4 h. ago Report warns China drug innovation fast gaining ground on US biotech

Report warns China drug innovation fast gaining ground on US biotech  FirstWord Pharma

Events

5 h. ago China’s NMPA Accepts New Drug Application for Tinengotinib Tablets for Advanced Cholangiocarcinoma

China’s NMPA Accepts New Drug Application for Tinengotinib Tablets for Advanced Cholangiocarcinoma  OncLive

Events

13 h. ago China–Cartel Nexus: The Liquidity Architecture Transforming the Global Drug Economy

China–Cartel Nexus: The Liquidity Architecture Transforming the Global Drug Economy  New Lines Institute

Events

3 d. ago China’s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?

Mainland China’s 17 million Alzheimer’s patients can, for the first time, pay less out of pocket for a costly drug touted as “historic” and “the beginning of the end” for the memory-robbing disease after Beijing launched a commercial insurance innovative drug list in an effort to make medicines more accessible and affordable. Leqembi, developed by Japan’s Eisai and costing a mainland Chinese patient about US$28,400 a year, could see its price cut by half after it was added to the inaugural...

Events

3 d. ago China’s new drug insurance: lifeline for patients or squeeze on big firms?

China’s new drug insurance: lifeline for patients or squeeze on big firms?  South China Morning Post

Events

3 d. ago Yarrow blooms with $1.37B deal, landing autoimmune thyroid disease drug from China’s GenSci

Yarrow blooms with $1.37B deal, landing autoimmune thyroid disease drug from China’s GenSci  Fierce Biotech

Economics

3 d. ago We crunched the numbers on drug discovery in the U.S. vs. China. The results were alarming

We crunched the numbers on drug discovery in the U.S. vs. China. The results were alarming  statnews.com

Events

3 d. ago Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

A Chinese biopharmaceutical firm has sealed a global licensing deal valued at up to US$1.44 billion, the second in a week, as a wave of cross-border tie-ups shows no sign of abating despite headwinds from the US Biosecure Act. Shanghai Scizeng Medical Technology, a unit of Changchun High-Tech Industry, has agreed to grant US-based Yarrow Bioscience exclusive global rights to develop, manufacture and commercialise GenSci098, an injectable therapy for thyroid eye disease and Graves’ disease, both...

Economics

3 d. ago China seizes 430kg of cocaine aided by US intel, a sign anti

Chinese authorities have intercepted 430kg (948lbs) of cocaine aided by tip-offs by the United States, a sign of possible progress on the issue following an agreement on counternarcotics cooperation reached by the leaders of the two countries in October. Chinese authorities had found the drug in an international container at the Yantian port in Shenzhen, southern China’s Guangdong province, on November 26, state broadcaster CCTV said on Tuesday. The case is under further investigation and no...

Politics

8 d. ago Abraham Accords allies may help US shift drug sourcing from China, report says

Abraham Accords allies may help US shift drug sourcing from China, report says  Fox Business

Events

9 d. ago China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma’s unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including...

Economics

1 week ago Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.

Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.  Barron's

Events

1 week ago Former chief of China’s food and drug watchdog ousted from Communist Party

Bi Jingquan, China’s former top food and drug regulator who received an international accolade for promoting innovation, has been expelled from the Communist Party and removed from public office on corruption charges. An investigation found that Bi had accepted gifts, money, trips and banquets and borrowed vehicles from private business owners, a statement from the Central Commission for Discipline Inspection (CCDI) said on Monday. The statement also said Bi had “allowed others to pay for him,...

Society

1 week ago To Beat China at Drug Innovation, Big Pharma and Generics Need the Supreme Court to End This Patent Absurdity

To Beat China at Drug Innovation, Big Pharma and Generics Need the Supreme Court to End This Patent Absurdity  IPWatchdog.com

Events

1 week ago Zai Lab Announces Updates to China’s National Reimbursement Drug List

Zai Lab Announces Updates to China’s National Reimbursement Drug List  Yahoo Finance Singapore

Events

2 w. ago World’s first ‘ethical AI’ wades into risks of China’s new drug abuse law

A new Chinese AI system called Wen Dao – billed as the world’s first such model to be designed explicitly for ethical risk detection – has landed in the middle of its first major moral dilemma. Its immediate challenge is to navigate one of 2025’s most explosive social debates: whether the country should automatically seal the records of convicted drug users under the newly revised Public Security Administration Punishments Law. Effective January 1, an amendment to the law known as Article 136...

Events

2 w. ago How China went from generic drug factory to biomedicine innovator

China’s pharmaceutical industry is on the brink of enormous growth and transformation. In just a few years, it has moved on from being the world’s cheapest source of active pharmaceutical ingredients to becoming a major hub for pharmaceutical innovation – a place where new, more effective drugs are born. It is now the second-largest developer of drugs, trailing only the United States. In the global drug development pipeline, China’s growth rate is phenomenal, leaping from 3 per cent in 2013 to...

Events

2 w. ago Opinion | How China went from generic drug factory to biomedicine innovator

Opinion | How China went from generic drug factory to biomedicine innovator  South China Morning Post

Events

2 w. ago How China engineered the rapid rise of its drug innovation industry

China’s pharmaceutical industry is on the brink of enormous growth and transformation. In just a few years, it has moved on from being the world’s cheapest source of active pharmaceutical ingredients to becoming a major hub for pharmaceutical innovation – a place where new, more effective drugs are born. It is now the second-largest developer of drugs, trailing only the United States. In the global drug development pipeline, China’s growth rate is phenomenal, leaping from 3 per cent in 2013 to...

Events

2 w. ago Opinion | How China engineered the rapid rise of its drug innovation industry

Opinion | How China engineered the rapid rise of its drug innovation industry  South China Morning Post

Events